Pyxis Oncology (PYXS) Stock Price, News & Analysis

Company Overview

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $1.55 to $1.63
• 50-Day Range: $1.52 to $4.74
• 52-Week Range: $1.49 to $6.85
• Volume: 643,053 shs
• Average Volume: 794,209 shs
• Market Capitalization: $96.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.43
• Consensus Rating: Moderate Buy

Pyxis Oncology Stock Analysis - MarketRank™

Pyxis Oncology scored higher than 46% of companies evaluated by MarketBeat, and ranked 632nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Pyxis Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Pyxis Oncology has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Pyxis Oncology are expected to decrease in the coming year, from ($1.03) to ($1.29) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pyxis Oncology is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pyxis Oncology is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pyxis Oncology has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.56% of the float of Pyxis Oncology has been sold short.

Short Interest Ratio / Days to Cover

Pyxis Oncology has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Pyxis Oncology has recently increased by 5.26%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pyxis Oncology does not currently pay a dividend.

Dividend Growth

Pyxis Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.56% of the float of Pyxis Oncology has been sold short.

Short Interest Ratio / Days to Cover

Pyxis Oncology has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Pyxis Oncology has recently increased by 5.26%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.34

News Sentiment

Pyxis Oncology has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Pyxis Oncology this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for PYXS on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

6 people have added Pyxis Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Pyxis Oncology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $174,146.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 9.80% of the stock of Pyxis Oncology is held by insiders.

Percentage Held by Institutions

Only 39.09% of the stock of Pyxis Oncology is held by institutions.

PYXS Stock Analysis - Frequently Asked Questions

How have PYXS shares performed this year?

Pyxis Oncology's stock was trading at $1.80 at the start of the year. Since then, PYXS shares have decreased by 10.0% and is now trading at $1.62.
View the best growth stocks for 2024 here.

How were Pyxis Oncology's earnings last quarter?

Pyxis Oncology, Inc. (NASDAQ:PYXS) announced its quarterly earnings results on Saturday, May, 11th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.19. The firm earned $16.15 million during the quarter, compared to analyst estimates of $4.25 million.

When did Pyxis Oncology IPO?

Pyxis Oncology (PYXS) raised $158 million in an initial public offering (IPO) on Friday, October 8th 2021. The company issued 10,500,000 shares at a price of $14.00-$16.00 per share.

Who are Pyxis Oncology's major shareholders?

Pyxis Oncology's top institutional shareholders include Geode Capital Management LLC (1.82%), State Street Corp (1.60%), abrdn plc (1.54%) and Jacobs Levy Equity Management Inc. (0.64%). Insiders that own company stock include Pfizer Inc, Lara Sullivan, Pamela Ann Connealy, Jitendra Wadhane and Mark Chin.
View institutional ownership trends.

How do I buy shares of Pyxis Oncology?

Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Pyxis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pyxis Oncology investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Walmart (WMT), Home Depot (HD) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 5/11/2024
• Today: 12/26/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PYXS
• CUSIP: N/A
• CIK: 1782223
• Web: www.pyxisoncology.com
• Phone: 617-221-9059
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.43
• High Stock Price Target: $13.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +482.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-73,790,000.00
• Net Margins: N/A
• Pretax Margin: -355.24%
• Return on Equity: -36.22%
• Return on Assets: -28.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.33
• Quick Ratio: 7.33

Sales & Book Value

• Annual Sales: $16.15 million
• Price / Sales: 5.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.81 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 59,466,000
• Free Float: 53,638,000
• Market Cap: $96.33 million
• Optionable: Optionable
• Beta: 1.00